Literature DB >> 6527232

Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions.

M W Lo, S M Pond, D J Effeney, B M Silber, S Riegelman, T N Tozer.   

Abstract

The formation of four major metabolites of propranolol by the liver was examined at steady state in three dogs that had undergone surgical portacaval transposition, following which injection of drug into the hindlimb delivers the total dose to the liver. Propranolol was infused directly into the liver via a hindlimb vein at dose rates ranging from 1.01 to 6.3 mg/min. In all dogs the formation of 4-hydroxypropranolol, alpha-naphthoxylactic acid, and propranolol glycol was saturable. Vmax and Km values were determined at steady state by relating the rate of excretion of each metabolite into bile and urine to the blood concentration of propranolol. The formation of propranolol glucuronide was a first order process. The use of a dog with a portacaval transposition has permitted development of a method to estimate, in vivo, the kinetic properties of enzymes responsible for hepatic first-pass metabolism of drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6527232     DOI: 10.1007/bf01062665

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  17 in total

1.  Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol.

Authors:  T Suzuki; S Isozaki; T Ishida; Y Saito; F Nakagawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1974-07       Impact factor: 1.645

2.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

3.  The pathways of propranolol metabolism in dog and rat liver 10,000g supernatant fractions.

Authors:  V T Vu; F P Abramson
Journal:  Drug Metab Dispos       Date:  1980 Sep-Oct       Impact factor: 3.922

4.  Dose-dependent elimination of propranolol and its major metabolites in humans.

Authors:  B M Silber; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

5.  A technique to study hepatic and intestinal drug metabolism separately in the dog.

Authors:  D J Effeney; S M Pond; M W Lo; B M Silber; S Riegelman
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition.

Authors:  M W Lo; D J Effeney; S M Pond; B M Silber; S Riegelman
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

7.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

8.  Stereoselective disposition and glucuronidation of propranolol in humans.

Authors:  B Silber; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1982-06       Impact factor: 3.534

9.  Identification of major sulfate conjugates in the metabolism of propranolol in dog and man.

Authors:  T Walle; U K Walle; D R Knapp; E C Conradi; E M Bargar
Journal:  Drug Metab Dispos       Date:  1983 Jul-Aug       Impact factor: 3.922

10.  Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.

Authors:  T Walle; U K Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-03
View more
  1 in total

Review 1.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.